K Santalahti1,2, A Havulinna3, M Maksimow1,2, T Zeller4,5, S Blankenberg4,5, A Vehtari6, H Joensuu7,8, S Jalkanen1,2, V Salomaa3, M Salmi1,2. 1. MediCity Research Laboratory, University of Turku, Turku, Finland. 2. Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland. 3. Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland. 4. Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany. 5. German Center for Cardiovascular Research (DZHK eV), Partner Site Hamburg/Lübeck/Kiel/Hamburg, Germany. 6. Department of Biomedical Engineering and Computational Science, Aalto University, Espoo, Finland. 7. Department of Oncology, Helsinki University Hospital, Helsinki, Finland. 8. University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Circulating levels of growth factors involved in leucocyte production and angiogenesis could be indicative of underlying aberrations of tissue homeostasis and therefore be utilized as predictors of risk for all-cause cardiovascular disease (CVD) or cancer mortality. METHODS: Baseline plasma levels of a range of growth factors were measured in two cohorts of the population-based FINRISK study (1997 Discovery cohort, N = 8444, aged 25-74; 2002 Replication cohort, N = 2951, aged 51-74 years) using a multiplexed bead array methodology and ELISA. Participants were followed up by linking them to registry data. RESULTS: In the Discovery cohort (653 deaths; 216 CVD-related, 231 cancer-related), fully adjusted Cox proportional hazard regression models showed that increased plasma hepatocyte growth factor (HGF) and placental growth factor (PlGF) were associated with higher risk of 10-year mortality (HR, 1.29 [95% confidence interval (CI), 1.18-1.41] and HR, 1.23 [95% CI, 1.14-1.32], respectively). In the Replication cohort (259 deaths; 83 CVD-related, 90 cancer-related), baseline HGF levels also predicted all-cause mortality (HR, 1.2 [95% CI, 1.08-1.32]; PlGF data not available). By including HGF levels in a CVD mortality model, 9% of all CVD deaths were correctly reclassified in the Discovery cohort (categorical net reclassification improvement [NRI] for events, P = 4.0 × 10-4 ). Moreover, adding HGF to all-cause and CVD mortality models resulted in an overall clinical NRI of 0.10-0.18 in the Discovery cohort and meta-analyses (P < 0.05 for all tests). CONCLUSION: Blood levels of HGF and PlGF may serve as new biomarkers for predicting increased risk of death in the general population.
BACKGROUND: Circulating levels of growth factors involved in leucocyte production and angiogenesis could be indicative of underlying aberrations of tissue homeostasis and therefore be utilized as predictors of risk for all-cause cardiovascular disease (CVD) or cancer mortality. METHODS: Baseline plasma levels of a range of growth factors were measured in two cohorts of the population-based FINRISK study (1997 Discovery cohort, N = 8444, aged 25-74; 2002 Replication cohort, N = 2951, aged 51-74 years) using a multiplexed bead array methodology and ELISA. Participants were followed up by linking them to registry data. RESULTS: In the Discovery cohort (653 deaths; 216 CVD-related, 231 cancer-related), fully adjusted Cox proportional hazard regression models showed that increased plasma hepatocyte growth factor (HGF) and placental growth factor (PlGF) were associated with higher risk of 10-year mortality (HR, 1.29 [95% confidence interval (CI), 1.18-1.41] and HR, 1.23 [95% CI, 1.14-1.32], respectively). In the Replication cohort (259 deaths; 83 CVD-related, 90 cancer-related), baseline HGF levels also predicted all-cause mortality (HR, 1.2 [95% CI, 1.08-1.32]; PlGF data not available). By including HGF levels in a CVD mortality model, 9% of all CVD deaths were correctly reclassified in the Discovery cohort (categorical net reclassification improvement [NRI] for events, P = 4.0 × 10-4 ). Moreover, adding HGF to all-cause and CVD mortality models resulted in an overall clinical NRI of 0.10-0.18 in the Discovery cohort and meta-analyses (P < 0.05 for all tests). CONCLUSION: Blood levels of HGF and PlGF may serve as new biomarkers for predicting increased risk of death in the general population.
Authors: Lars Wallentin; Niclas Eriksson; Maciej Olszowka; Tanja B Grammer; Emil Hagström; Claes Held; Marcus E Kleber; Wolfgang Koenig; Winfried März; Ralph A H Stewart; Harvey D White; Mikael Åberg; Agneta Siegbahn Journal: PLoS Med Date: 2021-01-13 Impact factor: 11.069
Authors: Lilin Li; Jung Nam An; Jeonghwan Lee; Dong Jin Shin; Shi Mao Zhu; Jin Hyuk Kim; Dong Ki Kim; Dong-Ryeol Ryu; Sejoong Kim; Jung Pyo Lee Journal: Kidney Res Clin Pract Date: 2021-09-10
Authors: Yong Chul Kim; Jung Nam An; Jin Hyuk Kim; Young-Wook Choi; Sohee Oh; Sang Ho Kwon; Mi-Young Lee; Junghun Lee; Jae-Gyun Jeong; Chun Soo Lim; Yon Su Kim; Seung Hee Yang; Jung Pyo Lee Journal: Sci Rep Date: 2018-08-24 Impact factor: 4.379